Latest signal
last curated pass Oct 3, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets
Recent curated signals
Algorithmic health The racing experiment runs: Johnson collects Lütke’s blood “before and after his 2.5 hr race,” calling it a first-in-world deep molecular profile On race day the announced experiment acquired data. At 15:10 UTC Johnson posted the physiological case for the weekend—Lütke driving “over 180 mph,” up to 4.2 g throwing his body forward with “715 lbs of force” and his head by “67 lbs,” braking requiring “up to 200 lbs of leg force,” a cockpit averaging “104-122°F,” core temperature reaching “102°F,” heart rate “140-170 bpm,” and up to “170 fl oz (5 kg)” of sweat and “11 lbs” of body-weight loss in a car with no driver cooling—then at 22:02 UTC closed the arc October 2 left open: “We completed a first-in-world racing experiment. I collected Tobi’s blood before and after his 2.5 hr race. This blood test is unique. It’s deep molecular profiling. What happens to the body under these extreme conditions?” The internal arithmetic is self-consistent (4.2 g on a ~170 lb driver ≈ 714 lb; 4.2 g on a ~16 lb head ≈ 67 lb; 5 kg of sweat ≈ 11 lb), and the physiology targets are literature-adjacent: measured endurance racing shows cockpits of ~40–50°C, heart rates of 159–170 bpm sustained for full stints, and sweat rates around 0.6 L/h with clinically meaningful dehydration over longer events (Carlson et al., J Strength Cond Res, 10.1519/JSC.0000000000002268). The boundaries: the headline numbers are Johnson’s own with no per-race telemetry source; the 5 kg sweat claim implies ~2 L/h for 2.5 hours—roughly triple the ~0.6 L/h typical of measured driver studies and a level literature associates with extreme conditions; and “deep molecular profiling” names no panel, analyzer, or method, so what was measured, when, and how it will be analyzed remain unstated. The dashboard records an attributed experiment narrative with verified context—not evidence that molecular profiling of drivers is novel or useful, a hydration or cooling protocol, or medical advice. 4 sourcesMethod export / motorsport physiology Research claims “Car racing is cognitive enhancement”: three research claims compressing NeuroRacer and driver-neuroscience findings An hour before the race, Johnson posted a three-claim case that racing itself is cognitive enhancement: “12 hrs on a driving video game, and 60-85 yr olds were cognitively overtaking 20 yr olds”; “race car drivers do in one brain region what a novice does in 15”; and “six months later, the seniors kept the gains with zero practice.” Two of the three anchor to real studies with the numbers matching closely. The first and third trace to Anguera et al. (Nature, 2013, 10.1038/nature12486): 12 hours of adaptive multitasking training on the NeuroRacer 3-D driving game over a month left 60–85-year-olds with multitasking costs better than untrained 20-year-olds’ single-session performance (−16.2% vs −36.7% cost), with gains persisting six months without booster sessions. The second traces to neural-efficiency work in actual drivers: Bernardi et al. (PLoS ONE, 2013, 10.1371/journal.pone.0077764) found professional racing drivers recruit a smaller volume of task-related regions than naïve drivers, and the follow-up structural study (Frontiers Hum Neurosci, 2014, 10.3389/fnhum.2014.00888) found pros more consistently recruiting motor-control and spatial-navigation areas with retrosplenial-cortex gray-matter density correlating with racing success. The boundaries: no study Johnson cites shows actual race-car driving enhancing cognition in drivers—the evidence runs from a custom video game in older adults and cross-sectional expert/novice comparisons, the latter unable to separate training from selection; “one brain region vs 15” is a compression, not a measured count; and the 6-month retention figure is from the game study’s older adults, not from any racing population. The dashboard records an attributed research-claims post with verified sources—not evidence that racing is a cognitive-enhancement intervention, a brain-training recommendation, or medical advice. 4 sourcesCognitive enhancement / driving expertise neuroscience Algorithmic health Algorithmic health goes to the race track: Johnson reviews a friend’s qualifying stint via “car stats, micro decisions, blood biomarkers” Johnson posted from the Motul Petit Le Mans weekend at Michelin Raceway Road Atlanta, where three friends—Shopify founder Tobi Lütke, Ruby on Rails creator DHH (David Heinemeier Hansson), and Le Mans podium finisher Mathias Beche—share the No. 11 TDS Racing ORECA LMP2 07 in the 10-hour IMSA season finale. The entry verifies against IMSA’s official entry list (54 cars, 2.54-mile 12-turn road course, green flag October 3, 12:10 p.m. ET), and both résumés check out: DHH won the GTE-Am class at the 2014 24 Hours of Le Mans with Aston Martin Racing, and Beche is a former ELMS LMP2 champion and 2014 Le Mans LMP1-L class winner with Rebellion Racing. The dashboard-relevant move is the second post: after Lütke “just got off the track” from qualifying, Johnson said he is now “reviewing Tobi’s performance via biomarkers”—“the car stats + his micro decisions + his blood biomarkers”—the algorithmic-health loop (telemetry, decisions, blood) applied to another person’s performance domain. The physiology framing is broadly literature-consistent: endurance racing measured in studies shows cockpit temperatures of roughly 40–50°C in multi-layer fireproof suits, heart rates of 159–170 bpm sustained for full stints (up to ~89% of age-predicted maximum), sweat rates around 0.6 L/h with clinically meaningful dehydration in longer races, and research protocols that themselves use ingestible core-temperature pills and continuous glucose monitors in driver-athletes (Carlson et al., J Strength Cond Res 2018; Frontiers Sports Act Living 2025). The boundaries: the headline “11 lbs of body weight” loss, “122°F cockpit,” “170 heart rate,” “4.2 g,” and “600–900 calories per hour” figures are Johnson’s own numbers with no per-race source; the biomarker review of Lütke is announced, not published—no panel, method, or result exists; and whether blood biomarkers add anything to established driver-science monitoring is untested. The dashboard records an attributed method-export and event narrative with verified racing context—not evidence that biomarker review improves driving performance, a training or hydration protocol, or medical advice. 6 sourcesMethod export / motorsport physiology Ideology Don’t Die borrows Levin’s “cognitive light cone”: a species measured by the wealth it spends on not dying Johnson quote-tweeted a post asking to “spend more than 0.05% of the federal NIH budget on studying the mechanisms of aging” and proposed that “the cognitive light cone of a species can be measured by the percent of wealth applied to securing its existence. The more advanced, the most it applies to not dying,” adding a follow-up crediting the term to @drmichaellevin. The attribution checks out: Levin coined “cognitive light cone” in “The Computational Boundary of a Self” (Frontiers in Psychology, 2019, 10.3389/fpsyg.2019.02688) as the spatio-temporal boundary of the goals an agent can represent and act on—though his definition concerns the scale of goal-directedness, not Johnson’s added “defend against thermodynamic entropy” gloss. The funding figure belongs to the quoted post rather than Johnson, and it matches only the narrowest line: NIA’s dedicated geroscience request is $25.0 million in the FY2027 President’s Budget—about 0.05% of NIH’s roughly $48 billion—while the broader Division of Aging Biology ran $342.3 million in FY2025 (≈0.7%), the “under 1%” share aging-biology advocacy cites. The dashboard records an attributed Don’t Die ideology formulation with verified term origin and budget context—not an established species-level metric, a funding recommendation, or medical advice. 4 sourcesDon’t Die ideology / aging-research funding N=1 test First night back at sea level: rebound deltas — sleep +13%, “nervous system” +17%, resting heart rate −12% The September 29 altitude readout acquired its epilogue: Johnson posted the first night back at sea level as mirror deltas—“sleep up 13%,” “nervous system up 17%,” “resting heart rate down 12%”—adding “my body slingshotted in rebound from 5 days of acute hypoxic stress.” The direction is consistent with published descent research: a randomized crossover trial in 44 healthy residents of moderate altitude (median home elevation 1,230 m) found that two nights at 590 m reduced nocturnal hypoxemia (time under 90% oxygen saturation 5→1 min), sleep-disordered breathing (AHI 14.2→9.2/h, ODI 10.0→6.0/h), and raised mean nocturnal SpO₂ 93.8%→95.2% versus living above 1,000 m, with significantly more slow-wave sleep on the second low-altitude night (Deflorin et al., J Clin Sleep Med, 10.1007/s44470-026-00128-1). The boundary: the post repeats the same proprietary wearable-index percentages as the altitude post—a sleep score and an Oura-style composite are not polysomnography—over a single recovery night with no baseline window; “slingshotted” is narrative framing, not a measured physiological rebound; and the trial studied altitude residents descending rather than a sea-level traveler returning from 7,000 ft, measuring breathing and oxygen rather than any wearable index. The dashboard records an attributed N=1 follow-up observation with literature-consistent direction—not evidence of a rebound effect, travel or sleep guidance, or medical advice. 2 sourcesAltitude / sleep and autonomic response N=1 test Five days at 7,000 ft read as wearable deltas: sleep −15%, “nervous system” −17%, resting heart rate +16% Johnson posted a travel-physiology readout after five days in Colorado and Wyoming at 7,000 ft (≈2,130 m): “sleep down 15%,” “nervous system down 17%,” “resting heart rate up 16%,” closing “Very happy to be back at sea level today.” The direction matches published moderate-altitude physiology: in 51 healthy lowland men studied at 490/1,630/2,590 m (Latshang et al., Sleep 2013, 10.5665/sleep.3242), altitude brought progressively worse periodic breathing (AHI 4.6/h at 490 m to 13.1/h on the first night at 2,590 m), lower mean nocturnal oxygen saturation (96%→90%), and reduced slow-wave sleep, while the same Zurich cohort recorded heart rate +3.3 bpm and mean blood pressure +4.8 mmHg at 2,590 m versus 490 m (PLOS ONE, 10.1371/journal.pone.0070081). The boundary: Johnson’s percentages are proprietary wearable-index deltas—a sleep score and an Oura-style “nervous system” composite are not polysomnography—over one trip with no baseline window disclosed; the same literature shows acclimatization by the second night, unchanged sleep efficiency and subjective sleepiness, no measurable vigilance decrement at these elevations, and even improved lipid profiles and hsCRP at altitude. The dashboard records an attributed N=1 wearable observation with verified literature direction—not evidence that moderate-altitude travel is harmful, a travel or sleep recommendation, or medical advice. 3 sourcesAltitude / sleep and autonomic response Testing Johnson quantifies household mold with a spore-trap air sampler and an outdoor control Johnson reported finding mold in his home gym after periodic air testing: 4,900 spores/m³ indoors versus a 360 spores/m³ outdoor control, dominated by penicillium/aspergillus at 4,800 spores/m³ with ulocladium at roughly 40, which he graded “stage 4, high.” A companion post explained the method: a Buck BioAire B520 pump pulls a calibrated air volume through a spore-trap cassette that deposits airborne particles onto a sticky slide, with spores then counted under a microscope. The structure is a familiar algorithmic-health move—quantify the environment with a device, use an outdoor control as the baseline, then subtract harm—but it is a single self-administered sample with no lab report, no species confirmation beyond microscopy, and no stated health outcome; “stage 4” is his grading, not a published exposure standard. The dashboard records an attributed N=1 environmental measurement—not a mold-remediation recommendation, an exposure-safety threshold, or medical advice. 2 sourcesEnvironmental health / mold measurement Female health The endometriosis program moves from diagnosis to a cure attempt with an MRI baseline Johnson wrote that he is “focusing a significant amount of my time trying to build a cure for Kate’s endometriosis,” calling it a devastating disease affecting 10% of women that is underfunded and poorly understood; a follow-up described a baseline pelvic MRI to map Tolo’s deep lesions, cysts, and scar tissue so any change can be tracked in detail. His framing statistics check out against published literature: endometriosis prevalence estimates run 6–10% of women of reproductive age, and his “average 6.6 years to diagnose” matches the mean diagnostic delay found in a 2024 international scoping review (Health Care Women Int.). The post also revises the July diagnosis story—“four specialty different tests (blood, MRI, saliva, transvaginal ultrasound)” in 42 days, where July’s announcement named three modalities. No cure method, target, trial, or outcome is published; the dashboard records an attributed program-intent update with verified epidemiologic context—not evidence a cure exists or is feasible, a diagnostic pathway readers can follow, or medical advice. 3 sourcesEndometriosis / cure program / diagnostic delay
// Reference paths
Move from feed to dossiers
Each route keeps source trails and medical caution visible. Protocol Health
Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.
Protocol LongevityHabits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.
Protocol NutritionHabits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.
Protocol SleepHabits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.
Reference Concepts39 source-aware glossary entries, including concepts without dedicated wiki pages yet.
entity BlueprintBlueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer
concept Blueprint ProtocolThe Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a
concept Don't DieDon't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a
concept Biomarker-driven longevity protocolsA biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre
Signal MetricsInspect source velocity by range, content type, and fallback API state.